|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The lipolytic protein LipU was conserved in mycobacterium sp. including M. tuberculosis (MTB LipU) and M. leprae (MLP LipU).
|
29557724 |
2019 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Mycobacterium tuberculosis specific LAMP assay ('MTB LAMP') showed sensitivity and specificity, of 44.7% and 94.4% respectively in a 60 min format, 85.7% and 93.9% respectively in a 90 min format and 91.7%, and 90.9% respectively in a 120 min format.
|
21047534 |
2011 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correlation of results of polymerase chain reaction for Mycobacterium tuberculosis (MTB PCR) with clinical features and treatment response in tubercular uveitis.
|
28665743 |
2018 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mycobacteria, including most of all MTB (Mycobacterium tuberculosis), cause pathogenic infections in humans and, during the infectious process, are exposed to a range of environmental insults, including the host's immune response.
|
20522025 |
2010 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of two alternative methods of pooling sputum prior to testing for tuberculosis with genexpert MTB/RIF.
|
31029099 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The performance was evaluated of a fluorescence in situ hybridisation assay using peptide nucleic acid probes (Dako Probe MTB Culture Confirmation Test; Dako, Denmark) for identification of Mycobacterium tuberculosis complex (MTC) organisms and differentiation between tuberculous and non-tuberculous mycobacteria (NTM) in material taken directly from Bactec 12B (Becton Dickinson, USA) and MB/BacT (Organon Teknika, USA) bottles.
|
10746504 |
2000 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite efforts to promote bi-directional screening of TB and DM, the uptake of TB testing among pre-diabetes and diabetes cases was only 4.7%, while the uptake of DM testing among MTB positive cases was 21.8%.
|
30841929 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatases A and B (PtpA and PtpB) have been recognized as potential molecular targets for the development of new therapeutic strategies against tuberculosis (TB).
|
29275228 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Mycobacterium tuberculosis</i>/human immunodeficiency virus (MTB/HIV) coinfection presents a special challenge to the prevention and treatment of tuberculosis and HIV/AIDS.
|
28861087 |
2017 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Cepheid Xpert(®) MTB/RIF assay has been credited with revolutionizing laboratory testing to aid in the diagnosis of TB and rifampicin-resistant TB.
|
25373876 |
2015 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Difficulty in obtaining large quantities of Mycobacterium tuberculosis (MTB) proteins remains a major obstacle in the development of subunit vaccines and diagnostic reagents for tuberculosis.
|
17401148 |
2007 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results confirm the reliability of the AMPLICOR MTB assay for direct detection of M. tuberculosis in AFB smear-positive sputum specimens and suggest a potential role in evaluating AFB smear-negative sputum specimens.
|
9154406 |
1997 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A ligase chain reaction (LCR) DNA amplification method for the molecular diagnosis of Mycobacterium tuberculosis (Abbott LCx MTB) was evaluated in comparison with solid and liquid phase culture on 622 selected samples collected in two large Italian hospitals, of which 310 obtained from HIV-1 positive patients and 312 from HIV-negative individuals.
|
9579333 |
1998 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that the Cobas Amplicor MTB test enables detection of tuberculosis in respiratory specimens, but does not perform well enough in non-respiratory specimens.
|
12953947 |
2003 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that the use of in vitro models of MTB-intracellular infection to select MTB gene products for further in silico and in vitro assessment of their immunogenicity have the potential to identify novel antigens amenable to the design of new tools for diagnosis and monitoring of tuberculosis.
|
19447677 |
2009 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although it is now widely used for tuberculosis (TB) diagnosis, Xpert(®) MTB/RIF availability remains inadequate in low-resource settings.
|
27393548 |
2016 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results were compared with those of three molecular assays: Xpert MTB/RIF assay (MTB is Mycobacterium tuberculosis), Sacace MTB Real-TM resistance, and AdvanSure MDR-TB GenoBlot assay (MDR is multidrug resisitant).
|
24797357 |
2015 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the number of patients that developed typical (Mycobacterium tuberculosis [MTB]) and atypical mycobacterial infections (AMI) while on treatment with ruxolitinib by utilizing the United States Food and Drug Administration (FDA) adverse events reporting system (FAERS).
|
31699655 |
2020 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert MTB/RIF was similar to other NATs (TaqMan MTB and TRCRapid M.TB) in terms of performance.
|
27919693 |
2017 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert® MTB/RIF in pleural fluid for the diagnosis of tuberculosis.
|
23827859 |
2013 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BDProbeTec MTB assay for direct detection of Mycobacterium tuberculosis was evaluated in comparison with the AMTD-II assay on 94 samples from different patients with clinical suspicion of tuberculosis.
|
15059123 |
2004 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report an 11-year-old girl with TB otitis media with negative smear microscopy and Xpert MTB/RIF but positive Mycobacterium tuberculosis-specific transrenal DNA (Tr-MTB-DNA) test results and culture for M. tuberculosis.
|
25339389 |
2015 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of Amplicor MTB test as adjunct to smears and culture for direct detection of Mycobacterium tuberculosis in the French Caribbean.
|
8727876 |
1996 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated several novel methods including Xpert Mycobacterium tuberculosis/rifampicin (Xpert MTB/RIF) technology, quantitative fluorescence Polymerase Chain Reaction (qPCR) and High-Resolution Melting Curve (HRMC) in the diagnosis of superficial lymph node TB.
|
31333119 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of vaccine antigens (Ags) by considering Mtb genetic diversity is crucial for the development of improved TB vaccine.
|
30753099 |
2019 |